In cases of chronic myeloid leukemia (CML), BCR-ABL1 inhibited the expression of miR-150, which contributed to a halt in myeloid differentiation and treatment resistance 65. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.